684286-95-1

Upstream product

• 684286-92-8 5-benzhydryloxy-7-(4-fluorobenzyl)-9-methoxy-pyrrolo[3,4-g]quinoxaline-6,8-dione 
• 684286-91-7 5-benzhydryloxy-7-(4-fluorobenzyl)-9-hydroxy-pyrrolo[3,4-g]quinoxaline-6,8-dione 
• 684286-90-6 carbonic acid 9-benzhydryloxy-7-(4-fluorobenzyl)-6,8-dioxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinoxalin-5-yl ester ethyl ester 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring

This communication details both the syntheses and biological evaluation of a novel class of HIV-1 integrase inhibitors. When the quinoline moiety is replaced with the quinoxoline moiety, the antiviral activity is significantly compromised. Similarly, intr

PHOSPHONATE ANALOGS OF HIV INTEGRASE INHIBITOR COMPOUNDS

Novel HIV integrase inhibitor compounds having at least one phosphonate group, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.

PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS

Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. Formula (I). Al and A2 are moieties forming a five, six, or seven membered ring. L is a bond or a linker connecting a ring atom of Ar to N. X is O, S, or substituted nitrogen. Ar is aryl or heteroaryl. Q is N, +NR, or CR4. The aryl carbons may be independently substituted with substituents other than hydrogen. The compounds may include prodrug moieties covalently attached at any site.